On August 29th, Gelonhui announced its semi-annual report for 2024, with reported revenue of 35.529 million yuan, a year-on-year decrease of 76.25%; net income attributable to shareholders of listed companies was 25.2744 million yuan, a year-on-year decrease of 76.65%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -21.3215 million yuan; basic earnings per share was 0.0421 yuan.
华兰疫苗(301207.SZ)：上半年净利润2527.44万元 同比下降76.65%
Hualan Vaccine (301207.SZ): The net income in the first half of the year was 25.2744 million yuan, a year-on-year decrease of 76.65%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.